Previous 10 | Next 10 |
We conclude our roundtable series with Biotech and Healthcare coverage. Seven of our Marketplace contributors give their analysis and share one top idea. Look for more roundtables and analysis this summer from our community of 180+ Marketpalce services. ~ By Tim Murphy, Ma...
BURNABY, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,098,362 common shares, which includes 1,229,508 shares...
Gainers: F-star Therapeutics (FSTX) +57%. Valneva (VALN) +23%. Nutriband (NTRB) +16%. Rain Therapeutics (RAIN) +15%. uniQure (QURE) +15%. Losers: Applied Therapeutics (APLT) -25%. Mereo BioPharma Group (MREO) -14%. Rigel Pharmaceuticals (RIGL) ...
Applied Therapeutics ( APLT ) -22% on pricing $30M equity offering . Xenon Pharmaceuticals ( XENE ) -13% on pricing $250M equity offering . Clovis Oncology ( CLVS ) -10% Zai Lab ( ZLAB ) -9% on conversion of secondary listing in Ho...
Xenon Pharmaceuticals (NASDAQ:XENE) shares dropped ~7.8% after-hours after the firm has priced its underwritten public offering of 7,868,854 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 327,868 common shares pursua...
BURNABY, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 7,868,854 common shares and, in lieu of common shares to certain investors, p...
Gainers: Seres Therapeutics (MCRB) +8%. Sana Biotechnology (SANA) +5%. Aziyo Biologics (AZYO) +4%. eXp World Holdings (EXPI) +4%. Aurora Innovation (AUR) +3%. Losers: Trip.com Group (TCOM) -9%. Xenon Pharmaceuticals (XENE) -8%. Accolade (ACCD) -6%. Ikena Oncology (IKNA) -6%. Cerus (...
Canadian biotech Xenon Pharmaceuticals (NASDAQ:XENE) dropped ~11% in the post-market Wednesday after the company announced an underwritten public offering of its common stock. A decision to grant a 30-day option for underwriters is also under consideration, allowing them to purchase...
New XEN1101 Phase 2b X-TOLE sub-group analysis demonstrates statistically significant efficacy results at all doses at Week 1, differentiating XEN1101 with rapid onset to seizure reduction New XEN1101 OLE data demonstrates continued seizure reduction exceeding 70% at ...
XEN1101 Phase 3 program for the treatment of focal onset seizures to be initiated in the second half of 2022 and New Drug Application expected to be submitted after completion of first Phase 3 clinical trial (X-TOLE2) along with the completed Phase 2b (X-TOLE) clinical trial ...
News, Short Squeeze, Breakout and More Instantly...
Xenon Pharmaceuticals Inc. Company Name:
XENE Stock Symbol:
NASDAQ Market:
Xenon Pharmaceuticals Inc. Website:
2024-06-25 17:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-15 18:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2024 in M...